NEW YORK (GenomeWeb) – Indian genomics testing firm Positive Bioscience announced today a partnership with Myriad Genetics to offer molecular diagnostic testing in that country. 

As part of the deal, Myriad will make available its tests covering nine cancers. They include BRACAnalysis to identify the risk of breast and ovarian cancer; Colaris to identify hereditary colorectal cancer; and myRisk, which assesses the risk of developing breast, prostate, endometrial, melanoma, pancreatic, colorectal, gastric, and ovarian cancer. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.